Table 1.
Main characteristics of studies included in the meta-analysis
| Study | Country | Inclusion period | Number of patients | Gender | Eye | Age | Clinical staging | Tumor invasion | Histological type | Preoperative treatment | Detection method | Expression evaluation standards | MMP types | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male/female | Right/left | /II+III | N0/NX | Well + moderately/poorly diff | ||||||||||
| Yun Li et al. (2006) | China | 1996–2005 | 30 | 18/12 | NA |
Range 4 month–6 years Median 2.9 years |
13/17 | 17/13 | 11/19 | NA | IHC | Proportion |
MMP-1 MMP-9 |
8 |
| Haiyan Li et al. (2012) | China | 2002–2011 | 52 | 31/21 | 33/29 |
Range 6 month–9 years Mean 5.1 ± 1.2 years |
NA | 28/24 | 24/28 | No chemo | IHC | Proportion + intensity |
MMP-1 MMP-9 VEGF |
7 |
| Siqi Yuan et al. (2010) | China | 2000–2009 | 31 | 23/18 | NA |
Range 5 month–9 years Median 3.3 years |
NA | 17/14 | 13/18 | NA | IHC | Proportion + intensity |
MMP-1 VEGF |
6 |
| Mohan Adithi et al. (2006) | India | 2000–2003 | 55 | 35/20 | 29/26 |
Range 1 month–14 years Median 2 years |
0/55 | 23/32 | 21/34 | No chemo | IHC | Proportion |
MMP-2 MMP-9 |
8 |
| Yang Yang et al. (2013) | China | 2001–2012 | 45 | 23/22 | 24/21 | Range 2 month–8 years | 36/9 | 26/19 | 17/28 |
No chemo No radio |
IHC | Proportion | MMP-2 | 6 |
| Lin Zhou et al. (2010) | China | 1989–2010 | 40 | 23/17 | 17/23 |
Range 4 month–18 years Median 2.9 years |
NA | 27/13 | 15/25 |
No chemo No radio |
IHC | Proportion + intensity |
MMP-2 MMP-9 VEGF |
6 |
| Jun Liang et al. (2017) | China | 2011–2016 | 100 | 66/34 | NA |
Range 4 month–11 years Median 4.2 years |
39/61 | NA | 55/45 | NA | IHC | Proportion + intensity |
MMP-9 VEGF |
8 |
| Yan Sun et al. (2014) | China | 2000–2011 | 56 | 29/27 | NA |
Range 3 month–7 years Mean 3.6 years |
20/16 | 28/28 | 31/25 | No chemo | IHC | Proportion + intensity | MMP-9 | 7 |
| Zhen Ge et al. (2007) | China | 1995–2005 | 32 | 19/13 | NA |
Range 4 month–10 years Median 3.1 years |
NA | 21/11 | 12/20 | No chemo | IHC | Proportion + intensity |
MMP-9 VEGF |
6 |
| Zixu Wu et al. (2011) | China | 2000–2010 | 41 | 23/18 | NA | NA | 29/12 | 24/17 | 20/21 | NA | IHC | Proportion + intensity | MMP-9 | 6 |
| Jia Yu et al. (2009) | China | 1990–2006 | 47 | 25/12 | 20/27 | Range 6 month–10 years | NA | 32/15 | 17/30 |
No chemo No radio |
IHC | Proportion + intensity |
MMP-9 VEGF |
6 |
| Yuejun Liu et al. (2014) | China | 2010–2014 | 30 | 18/12 | NA | Mean 5.2 years | NA | 17/13 | 12/18 | No chemo | IHC | Proportion + intensity | MMP-9 | 6 |
| Ying Jiang et al. (2004) | China | 1999–2002 | 22 | NA | NA |
Range 2 month–5 years Mean 2.4 years |
NA | 14/8 | 8/14 |
No chemo No radio |
IHC | Proportion | VEGF | 7 |
| Nermeen S Youssef et al. (2014) | Egypt | 2009–2013 | 56 | 24/32 | 23/40 | Mean 20.94 m ± 11.75 months | NA | 26/30 | 36/20 | No preoperative adjunctive treatments | IHC | percentage | VEGF | 8 |
| Lijuan Meng et al. (2011) | China | NA | 48 | 27/21 | 22/26 | Range 5 month–8y | NA | 21/27 | 19/29 |
No chemo No radio |
IHC | Proportion × intensity |
MMP-9 VEGF |
6 |
| Li Fang et al. (2010) | China | 2000–2007 | 33 | 18/15 | 14/19 | Range 6 month–9 years | NA | 22/11 | 12/21 |
No chemo No radio |
IHC | Proportion + intensity | VEGF | 6 |
m month, y year, IHC immunohistochemistry, NA not available, chemo chemotherapy, radi radiation therapy, diff differentiation, N0: absent local invasion, Nx optic nerve, optic nerve, choroidal, or scleral invasion, Proportion percentage of positive cells, intensity staining intensity of positive cells